A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2(-) advanced breast cancer

Erstveröffentlichung
2015
Metadata only
Search for full text
Wissenschaftlicher Artikel


Authors
Jerusalem, Guy
Bachelot, Thomas
Barrios, Carlos
Neven, Patrick
Di Leo, Angelo
et al.
Institutions
UKU. Klinik für Frauenheilkunde und Geburtshilfe
Published in
Cancer Treatment Reviews ; 41 (2015), 2. - S. 94-104. - ISSN 0305-7372. - eISSN 1532-1967
Link to publication
https://dx.doi.org/10.1016/j.ctrv.2014.12.011
Keywords
Endocrine therapy; Everolimus; Hormone receptor-positive advanced breast cancer; mTOR inhibitor; Overall survival; Progression-free survival; EVEROLIMUS PLUS EXEMESTANE; INTERNATIONAL CONSENSUS GUIDELINES; PLACEBO-CONTROLLED TRIAL; RANDOMIZED PHASE-II; DOUBLE-BLIND; AROMATASE INHIBITORS; RAPAMYCIN PATHWAY; MAMMALIAN TARGET; WOMEN
Dewey Decimal Group
DDC 610 / Medicine & health
Metadata
Show full item record